5 Settembre 2022
Loft N, Egeberg A, Rasmussen MK, et al.

Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study

J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1284-1291
  • Il presente studio ha avuto l’obiettivo di identificare e caratterizzare i pazienti con psoriasi refrattaria alla terapia e i pazienti super-responder al trattamento con farmaci biologici.
  • Una piccola proporzione di pazienti affetti da psoriasi trattati con biologici sono super-responder o refrattari al trattamento.
  • I super-responder hanno mostrato minori comorbilità e uno status socioeconomico più elevato, mentre i secondi un maggior peso corporeo.


Treatment with biologics often leads to clearance of psoriasis. However, some patients do repeatedly fail to respond and/or lose an achieved response (treatment refractory) to the biologic, whereas other patients achieve excellent response to one biologic and remain clear of psoriasis for several years (super-responders).

To identify and characterize patients with treatment refractory psoriasis and patients who are super-responders to biologic treatment.

Material and methods
Patients registered in DERMBIO between January 2007 and November 2019 were included. Patients were categorized as being treatment refractory if they had had treatment failure to ≥3 biologics targeting ≥2 different pathways. Super-responders were patients treated with their first biologic for minimum 5 years without an absolute psoriasis area and severity index (PASI) >3 between 6 months and 5 years of treatment. All remaining patients from DERMBIO served as comparators.

In total, 3280 patients were included with a mean age of 45.0 years. 1221 (37%) of the patients were females. Of the included patients, 214 (6.5%) were categorized as treatment refractory and 207 (6.3%) were categorized as super-responders. Treatment refractory patients had higher mean body weight (100.6 kg vs. 90.6 kg, p <0.0001) and higher mean BMI (32.2 vs. 29.4, p <0.0001) compared with the rest of patients in DERMBIO. Super-responders had higher socioeconomic status and fewer comorbidities compared with the comparator group (p <0.0001).

A small proportion of patients with psoriasis treated with biologics are either super-responders or treatment refractory. Treatment refractory patients have higher body weight, whereas super-responders have fewer comorbidities and higher socioeconomic status.

Tagged on:
Accedi all’abstract originale